Breaking News, Collaborations & Alliances

Catalent, InterveXion Announce First Enrollment in STAMPOUT

The first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200

Catalent Pharma Solutions announced that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200. STAMPOUT will be a phase 2a, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users.   Catalent has supported InterveXion by engineering the cell line which expresses the drug’s antibody e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters